<DOC>
	<DOCNO>NCT00462384</DOCNO>
	<brief_summary>This single arm study ass efficacy safety subcutaneous Mircera correction anemia participant chronic kidney disease dialysis treat erythropoiesis-stimulating agent ( ESA ) . Eligible participant receive Mircera monthly subcutaneous injection , dependent body weight ( start dose 1.2 micrograms/kilogram [ mcg/kg ] ) . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera Treatment Anemia Pre-Dialysis Participants With Chronic Kidney Disease .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>chronic kidney disease , stage 3 4 ; anemia ( baseline hemoglobin 9 11 gram per deciliter [ g/dL ] ) . previous therapy ESA within 12 week prior screen ; significant acute chronic bleed overt gastrointestinal bleeding ; red blood cell transfusion within 8 week screen ; active malignant disease ( except nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>